AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 352.7% in September

AstraZeneca PLC (OTCMKTS:AZNCF) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 42,100 shares, a growth of 352.7% from the August 31st total of 9,300 shares. Based on an average trading volume of 2,800 shares, the days-to-cover ratio is currently 15.0 days.

AstraZeneca Trading Down 3.7 %

Shares of AZNCF traded down $5.80 during trading hours on Wednesday, reaching $149.34. 6,361 shares of the company traded hands, compared to its average volume of 2,880. AstraZeneca has a 12 month low of $118.16 and a 12 month high of $175.00. The company’s fifty day moving average price is $162.63 and its two-hundred day moving average price is $152.89.

AstraZeneca Cuts Dividend

The firm also recently announced a dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were issued a dividend of $1.00 per share. The ex-dividend date of this dividend was Wednesday, August 7th. AstraZeneca’s dividend payout ratio (DPR) is presently 343.14%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AstraZeneca stock. Kennedy Capital Management LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 37,554 shares of the company’s stock, valued at approximately $5,068,000. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.